Tracking safety of Lorviqua in ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is collecting real-world safety information about Lorviqua (lorlatinib) in adults in Korea who have ALK-positive metastatic non-small cell lung cancer. It helps monitor side effects and safe use after the medicine is already on the market.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult using Lorviqua for ALK-positive metastatic non-small cell lung cancer
- You (or your legal representative) must sign and date an informed consent form
- Lorviqua must be allowed for you based on local label warnings (no contraindications)
- You must not have a known allergy or severe reaction to Lorviqua or its ingredients
- You should not be taking strong medicine that can speed up drug breakdown (strong CYP3A4/5 inducers)
- You must be able to take medicines that contain lactose (and not have certain rare lactose-related conditions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This study looks at what happens when lung cancer stops responding to the drug lorlatinib, which is used as the first treatment for ALK-positive non-small cell lung cancer. It aims to find out why the drug stops working and what the next best treatment might be, which could help guide future care.
This study looks at different ways to manage high cholesterol (hyperlipidemia) that happens as a side effect of the drug lorlatinib, which is used to treat ALK-positive lung cancer. Participants will receive additional cholesterol-lowering medicines or strategies, and the study aims to find the best way to keep cholesterol in check while continuing effective cancer treatment.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Hear when a new Metastatic ALK+ Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.